How to treat excessive sweating

Sweating is a normal part of temperature control. Hyperhidrosis is different: the amount of sweating is greater than the body needs for cooling, can occur without heat or exercise, and may interfere with daily activities. The important first step is not to choose a treatment — it is to understand why the sweating is happening.

Some people have primary focal hyperhidrosis, where sweating is excessive without another disease explaining it and commonly affects areas such as the underarms, palms, soles or face. Others have secondary hyperhidrosis caused by a medical condition, a medicine or another identifiable trigger. The treatment pathway is not the same for both.

Treatment options for excessive sweating include antiperspirants, prescription treatments, iontophoresis, microwave thermolysis and injectable treatment. A useful guide explains the full treatment ladder, where evidence is strongest, where licensing differs by body area and when sweating should be medically investigated before any procedure is considered.

Normal sweating increases with heat, exercise, fever or emotional stress. Hyperhidrosis describes sweating that is excessive for thermoregulation and can occur even when the body does not need to cool down. It can be focal — affecting one or several defined areas — or more generalised.

The NHS advises considering medical review when excessive sweating has lasted at least six months, occurs at least weekly, interferes with ordinary activities, happens at night, runs in the family or may be related to another medicine. Those criteria are useful because they shift the conversation away from “how much sweat is too much?” and towards duration, pattern and effect on daily life.

Primary focal hyperhidrosis often starts earlier in life and commonly affects the palms, soles, underarms or face. It can have a substantial quality-of-life impact, but the severity is not defined by appearance alone. A patient who changes clothes several times a day, avoids handling paper because of wet palms or struggles with footwear may have a clinically important problem even if the skin looks normal during a consultation.

The most important diagnostic divide is between primary hyperhidrosis and secondary hyperhidrosis. Primary hyperhidrosis is diagnosed when excessive sweating is not better explained by another medical condition or medicine. Secondary sweating has an identifiable cause that needs attention in its own right.

Examples of secondary causes include endocrine or metabolic disorders such as hyperthyroidism or diabetes, neurological disease, infection, menopause-related symptoms and medication effects. This is not an exhaustive list, and the significance depends on the pattern of sweating and other symptoms.

Not every person who sweats heavily needs extensive testing, but some patterns should not be approached as a cosmetic concern. Regular drenching night sweats, unexplained weight loss, fever, persistent cough, new palpitations, tremor, symptoms of low blood sugar or a sudden change in sweating pattern are examples of features that can justify medical assessment.

Medication review is also important. The NHS notes that excessive sweating can occur as a side effect of medicines. Antidepressants, some pain medicines, steroids and other drugs are among medications commonly discussed in the context of sweating or night sweats. A prescribed medicine should not be stopped solely because sweating develops; the appropriate step is to discuss the symptom with the prescriber.

Generalised sweating that starts abruptly deserves a different level of curiosity from longstanding symmetrical palmar sweating that began in adolescence. Good treatment starts by noticing that difference.

Hyperhidrosis is usually assessed through history and examination rather than one definitive laboratory test. The clinician asks where sweating occurs, when it started, whether it is symmetrical, whether it happens during sleep, whether relatives have similar symptoms and how much it interferes with work, clothing, sleep, social activity or practical tasks.

The pattern can then be checked against recognised diagnostic criteria for primary focal hyperhidrosis. A 2024 diagnostic study confirmed the importance of the core history of focal visible excessive sweating for at least six months without an apparent cause, while also highlighting that diagnostic tools still have limitations and are not perfect substitutes for clinical judgement.

If secondary hyperhidrosis is possible, examination and selected investigations are guided by the history rather than ordered mechanically for everyone. The Summary of Product Characteristics for a UK-authorised botulinum toxin product specifically requires history, examination and additional investigations as appropriate to exclude potential causes of secondary hyperhidrosis before treatment of primary axillary sweating.

For many patients, the first useful changes are simple rather than procedural. The NHS suggests loose-fitting clothing, moisture-absorbing socks, changing socks when needed, rotating leather footwear and avoiding obvious personal triggers such as alcohol or spicy food if they consistently worsen sweating.

These measures do not “cure” primary hyperhidrosis, but they can reduce visible sweat, odour, skin maceration and the daily inconvenience of the condition. Sweat shields, foot powders and gentler soap substitutes can also be useful adjuncts.

A pharmacist can advise on stronger antiperspirants available without prescription. It is worth distinguishing antiperspirant from deodorant: deodorant mainly addresses odour, whereas antiperspirant is designed to reduce sweat reaching the skin surface.

Aluminium-salt antiperspirants remain a common first-line treatment for focal hyperhidrosis. NICE’s evidence summary describes self-help and antiperspirants containing aluminium chloride hexahydrate as an initial approach before escalation to specialist options.

Concentrated aluminium chloride can irritate skin, particularly if applied to damp or recently shaved areas. Application schedules therefore need to balance effectiveness and tolerability. Irritation may be managed by adjusting frequency and using appropriate skin care, but persistent dermatitis should be reviewed rather than simply tolerated.

Topical prescription treatments are also available in some settings. Availability, licensing, body-area indication and adverse-effect profile differ between products, so a generic blog should not imply that every topical medicine is appropriate for every site.

Iontophoresis uses a weak electrical current passed through water, or through a wet pad, to reduce sweating. It is most commonly used for palmar and plantar hyperhidrosis because hands and feet are easy to place in treatment trays.

Treatment usually requires an initial series followed by maintenance. The exact schedule varies by device and response, so it is better described as a repeated management strategy than a one-off procedure. NICE includes iontophoresis among second-line options for primary hyperhidrosis, and the NHS lists it as a specialist treatment for severe sweating.

It is not suitable for everyone. Contraindications and precautions depend on the device and can include certain implanted electrical devices and pregnancy. Patients should follow device-specific medical guidance rather than self-selecting treatment from internet instructions.

Oral medicines that reduce cholinergic signalling can reduce sweating across more than one body area, which can be useful in generalised or multifocal disease. Their limitation is that the same mechanism that reduces sweat can also produce systemic anticholinergic effects.

A systematic review of oral anticholinergic treatment found symptom improvement in many patients but also frequent adverse effects, particularly dry mouth, and noted that the overall evidence base was limited. Other possible effects include blurred vision, constipation, urinary difficulty, palpitations and heat-intolerance concerns, depending on the medicine and dose.

This is why oral treatment needs individual prescribing rather than consumer-style recommendations. Some medicines used in hyperhidrosis are licensed for that indication; others may be used off-label. The choice depends on comorbidities, other medicines, heat exposure, occupation and tolerability.

Prescription-only botulinum toxin type A is one established option for severe focal axillary hyperhidrosis that has not responded adequately to topical treatment. It works by blocking acetylcholine release at cholinergic nerve endings, temporarily reducing stimulation of eccrine sweat glands in the injected area.

The evidence is strongest for axillary disease. Randomised trials and systematic reviews support a clinically meaningful reduction in axillary sweating and improvement in quality-of-life measures, but effect duration varies and repeat treatment may be needed when benefit wears off.

Licensing also matters. A current UK Summary of Product Characteristics for one authorised botulinum toxin type A product includes severe primary axillary hyperhidrosis that does not respond to topical antiperspirants. Treatment of other sites such as hands, feet or face may be off-label depending on the specific product and indication, and should not be presented as if all body areas share the same licence or evidence base.

This is a prescription-only medicine in the UK. It therefore belongs in a consultation-led medical pathway rather than promotional consumer advertising. Product choice, dose, indication, contraindications and risks must be assessed by an appropriate prescriber and treating clinician.

Microwave-based thermolysis is a device treatment designed to heat and damage sweat glands in the axilla. It is therefore relevant mainly to underarm hyperhidrosis, not to palmar, plantar or facial sweating.

A systematic review of five clinical trials involving 189 patients found encouraging reductions in axillary sweating but also concluded that the evidence base was small and that further work was needed to define long-term efficacy and safety. More recent reviews continue to describe microwave devices as an option within the axillary treatment landscape rather than as a universal first-line therapy.

Device-based treatment can involve swelling, tenderness, altered sensation and other local effects. The type of device, operator training, tissue anatomy and patient selection matter, so claims such as “permanent sweat removal” would be too absolute.

Surgery is generally reserved for severe disease when conservative and less invasive treatments have failed or are unsuitable. Procedures can include local sweat-gland surgery or sympathetic surgery, depending on the site and clinical context.

Endoscopic thoracic sympathectomy can reduce palmar and some other forms of focal hyperhidrosis, but compensatory sweating elsewhere on the body is a major long-term trade-off. A 2025 meta-analysis found compensatory hyperhidrosis to be common after sympathectomy, with severe compensatory sweating occurring in a meaningful minority of patients.

NHS commissioning policies that fund sympathectomy commonly position it after trials of aluminium salts, dermatology-led management, oral anticholinergic treatment, iontophoresis for palmar/plantar disease or injectable treatment for axillary disease. That sequencing reflects the irreversible or difficult-to-reverse nature of sympathetic surgery and the importance of counselling about compensatory sweating before proceeding.

Hyperhidrosis treatment is highly site-dependent. A practical option for the palms may be inconvenient or ineffective for the face; a treatment supported for the axilla may not have the same licence or evidence for the feet.

Hyperhidrosis is usually managed rather than “cured”. Some interventions work only while they are being used. Antiperspirants require ongoing application. Iontophoresis commonly needs maintenance. Oral medication works while the medicine is taken and tolerated. Prescription-only injectable treatment wears off over time. Device or surgical approaches may provide longer-lasting change but introduce a different risk profile.

For this reason, fixed promises about how quickly results appear, how long they last or whether recovery is needed are too simplified when applied to hyperhidrosis treatment as a whole. Onset, duration and recovery depend on the intervention, the body area and the individual.

For a licensed axillary botulinum toxin product, clinical benefit is temporary and product information governs dose, timing and repeat treatment. For iontophoresis, benefit depends on continued maintenance. For surgery, the trade-off is not temporary downtime but the possibility of long-term compensatory sweating. A treatment plan should make those differences explicit.

Current evidence supports a stepped, individualised approach. The NHS starts with practical measures and stronger antiperspirants, then lists specialist options including tablets, topical medicine, iontophoresis, axillary prescription-only injectable treatment and surgery. NICE similarly places aluminium salts early and escalation options later when initial measures are inadequate or unacceptable.

A 2026 review of pharmacological management describes aluminium salts, topical anticholinergic agents, oral treatment and botulinum toxin alongside iontophoresis, device-based therapies and surgery. The review reinforces that there is no single treatment that fits every phenotype of hyperhidrosis.

The MHRA issued updated warnings in 2026 about rare but serious iatrogenic botulism after botulinum toxin type A products and reaffirmed that these are prescription-only medicines. For a public-facing clinic article, the safest approach is therefore educational, consultation-led and free from product promotion, urgency, discounts or claims of guaranteed dryness.

Related treatment: Hyperhidrosis treatment